Ritu Baral: Great, thanks.
Operator: Thank you very much. One moment for our next question.
Sandy Macrae: And if I may, Ritu, we’ve started the — we’ve initiated the conversations with the Europeans and uniquely the FDA is volunteering to send one of their staff with us to that conversation because they feel that it’s the way forward for these kind of therapies is for a common approach to them. And I think it reflects the support that we have from the FDA in these discussions.
Ritu Baral: Thanks, Sandy.
Operator: Thank you very much. Our next question comes from the line of Nicole Germino of Truist. Nicole, your line is open.
Bill Chappell: Hi, this is Bill on for Nicole. We have a question, it’s given the uptake for Roctavian, what is the read through to potential uptake for Fabry disease gene therapy?
Sandy Macrae: Thank you for your question. So the Roctavian launch I know has been a subject of great debate. We can’t comment on how BioMarin launched it. All I know is the reason that we chose Pfizer to be our partner is I have great confidence that when Pfizer chooses to launch something, they do it well and effectively. And that follows through to our choice of partners for Fabry disease. There are several companies and there are some that are more obvious as being great commercialization engines and great launch companies. What I can tell you is in our conversations with these companies, we have had notes from the patient support groups, who have been very keen to make sure that the pharma partners understand how supportive they are of the results that they have seen in our Fabry program.
Because you and I will talk about the biochemistry and the biopsies. What the patients have said is how much better they feel on it, how delighted that they are to be off of ERT. So now we have 14 patients off of ERT and the four that are remaining on ERT in the study have already booked when they’re going to come off of the therapy. So this has enormous support from the patients and I think that is what is going to make it a very successful launch for the partner that can take it forward and make a difference.
Amy Pooler: And if I may add, we also have R-MAT and Prime, which are designations that really analogize an unmet medical need for Fabry. So the Fabri patients, even though they can have access to ERT, are not satisfied with the current medicine and standard-of-care.
Bill Chappell: Thank you so much.
Operator: Thank you very much. At this time, I’m showing no further questions, and I would now like to turn the call back to Louise Wilkie for closing remarks.
Louise Wilkie: Thank you very much and thanks to everyone for joining us on the call today. We look forward to speaking to you soon.
Operator: Thank you for your participation in today’s conference. This does conclude the program and you may now disconnect. Thank you.
